Also found in: Dictionary.


(proe-poe-fol) ,


(trade name)


Therapeutic: general anesthetics
Pregnancy Category: B


Induction of general anesthesia in children >3 yr and adults.Maintenance of balanced anesthesia when used with other agents in children >2 mo and adults.Initiation and maintenance of monitored anesthesia care (MAC).Sedation of intubated, mechanically ventilated patients in intensive care units (ICUs).


Short-acting hypnotic. Mechanism of action is unknown.
Produces amnesia.
Has no analgesic properties.

Therapeutic effects

Induction and maintenance of anesthesia.


Absorption: Administered IV only, resulting in complete absorption.
Distribution: Rapidly and widely distributed. Crosses the blood-brain barrier well; rapidly redistributed to other tissues. Crosses the placenta and enters breast milk.
Protein Binding: 95–99%.
Metabolism and Excretion: Rapidly metabolized by the liver.
Half-life: 3–12 hr (blood-brain equilibration half-life 2.9 min).

Time/action profile (loss of consciousness)

IV40 secunknown3–5 min
†Time to recovery is 8 min (up to 19 min if opioid analgesics have been used)


Contraindicated in: Hypersensitivity to propofol, soybean oil, egg lecithin, or glycerol; Obstetric: Crosses placenta; may cause neonatal depression; Lactation: Enters breast milk; effects on newborn unknown.
Use Cautiously in: Cardiovascular disease;Lipid disorders (emulsion may have detrimental effect);↑ intracranial pressure;Cerebrovascular disorders;Hypovolemic patients (lower induction and maintenance dosage reduction recommended); Pediatric: Not recommended for induction of anesthesia in children <3 yr, or for maintenance of anesthesia in infants <2 mo; not for ICU or pre-procedure sedation; Geriatric: Lower induction and maintenance dose reduction recommended.

Adverse Reactions/Side Effects

Central nervous system

  • dizziness
  • headache


  • apnea
  • cough


  • bradycardia (most frequent)
  • hypotension (most frequent)
  • hypertension


  • abdominal cramping
  • hiccups
  • nausea
  • vomiting


  • flushing


  • burning (most frequent)
  • pain (most frequent)
  • stinging (most frequent)
  • coldness
  • numbness
  • tingling at IV site


  • involuntary muscle movements
  • perioperative myoclonia


  • discoloration of urine (green)


  • propofol infusion syndrome (life-threatening)
  • fever


Drug-Drug interaction

Additive CNS and respiratory depression with alcohol, antihistamines, opioid analgesics, and sedative/hypnotics (dose ↓ may be required).Theophylline may antagonize the CNS effects of propofol.Propofol may ↑ levels of alfentanil.Cardiorespiratory instability can occur when used with acetazolamide.Serious bradycardia can occur with concurrent use of fentanyl in children.↑ risk of hypertriglyceridemia with intravenous fat emulsion.


General Anesthesia
Intravenous (Adults <55 yr) Induction—40 mg q 10 sec until induction achieved (2–2.5 mg/kg total). Maintenance—100–200 mcg/kg/min. Rates of 150–200 mcg/kg/min are usually required during first 10–15 min after induction, then ↓ by 30–50% during first 30 min of maintenance. Rates of 50–100 mcg/kg/min are associated with optimal recovery time. May also be given intermittently in increments of 25–50 mg.
Intravenous (Geriatric Patients, Cardiac patients, Debilitated Patients, or Hypovolemic Patients) Induction—20 mg q 10 sec until induction achieved (1–1.5 mg/kg total). Maintenance—50–100 mcg/kg/min (dose in cardiac anesthesia ranges from 50–150 mcg/kg/min depending on concurrent use of opioid).
Intravenous (Adults Undergoing Neurosurgical Procedures) Induction—20 mg q 10 sec until induction achieved (1–2 mg/kg total). Maintenance—100–200 mcg/kg/min.
Intravenous (Children ≥3 yr–16 yr) Induction—2.5–3.5 mg/kg, use lower dose for children ASA III or IV.
Intravenous (Children 2 mo–16 yr) Maintenance—125–300 mcg/kg/min (following first 30 min of maintenance, rate should be ↓ if possible), younger children may require larger infusion rates compared to older children.
Monitored Anesthesia Care (MAC) Sedation
Intravenous (Adults <55 yr) Initiation—100–150 mcg/kg/min infusion or 0.5 mg/kg as slow injection. Maintenance—25–75 mcg/kg/min infusion or incremental boluses of 10–20 mg.
Intravenous (Geriatric Patients, Debilitated Patients, or ASA III/IV Patients) Initiation—Use slower infusion or injection rates. Maintenance—20% less than the usual adult infusion dose; rapid/repeated bolus dosing should be avoided.
ICU Sedation
Intravenous (Adults) 5 mcg/kg/min for a minimum of 5 min. Additional increments of 5–10 mcg/kg/min over 5–10 min may be given until desired response is obtained. (Range 5–50 mcg/kg/min.) Dose should be reassessed every 24 hr.

Availability (generic available)

Injection: 10 mg/mL

Nursing implications

Nursing assessment

  • Assess respiratory status, pulse, and BP continuously throughout propofol therapy. Frequently causes apnea lasting ≥60 sec. Maintain patent airway and adequate ventilation. Propofol should be used only by individuals experienced in endotracheal intubation, and equipment for this procedure should be readily available.
  • Assess level of sedation and level of consciousness throughout and following administration.
  • When using for ICU sedation, wake-up and assessment of CNS function should be done daily during maintenance to determine minimum dose required for sedation. Maintain a light level of sedation during these assessments; do not discontinue. Abrupt discontinuation may cause rapid awakening with anxiety, agitation, and resistance to mechanical ventilation.
  • Monitor for propofol infusion syndrome (severe metabolic acidosis, hyperkalemia, lipemia, rhabdomyolysis, hepatomegaly, cardiac and renal failure). Most frequent with prolonged, high-dose infusions (>5 mg/kg/hr for >48 hr) but has also been reported following large-dose, short-term infusions during surgical anesthesia. If prolonged sedation or increasing dose is required, or metabolic acidosis occurs, consider alternative means of sedation.
  • If overdose occurs, monitor pulse, respiration, and BP continuously. Maintain patent airway and assist ventilation as needed. If hypotension occurs, treatment includes IV fluids, repositioning, and vasopressors.

Potential Nursing Diagnoses

Ineffective breathing pattern (Adverse Reactions)
Risk for injury (Side Effects)


  • Do not confuse Diprivan (propofol) with Diflucan (fluconazole) or Ditropan (oxybutynin).
    • Dose is titrated to patient response.
    • Propofol has no effect on the pain threshold. Adequate analgesia should always be used when propofol is used as an adjunct to surgical procedures.
  • Intravenous Administration
  • pH: 7.0–8.5.
  • Diluent: Usually administered undiluted. If dilution is necessary, use only D5W. Shake well before use. Solution is opaque, making detection of contaminants difficult. Do not use if separation of the emulsion is evident. Contains no preservatives; maintain sterile technique and administer immediately after preparation.Concentration: Undiluted: 10 mg/mL. If dilution is necessary, dilute to concentration ≥2 mg/mL.
    • Discard unused portions and IV lines at the end of anesthetic procedure or within 6 hr. For ICU sedation, discard after 12 hr if administered directly from vial or after 6 hr if transferred to a syringe or other container. Do not administer via filter <5–micron pore size.
    • Aseptic technique is essential. Solution is capable of rapid growth of bacterial contaminants. Infections and subsequent deaths have been reported.
  • Rate: Administer over 3–5 min. Titrate to desired level of sedation. Frequently causes pain, burning, and stinging at injection site; use larger veins of the forearm, antecubital fossa, or a dedicated IV catheter. Lidocaine 10–20 mg IV may be administered prior to injection to minimize pain. Pediatric: Induction doses may be administered over 20–30 seconds.
  • Intermittent/Continuous Infusion: Diluent: Administer undiluted. Allow 3 to 5 min between dose adjustments to allow for and assess the clinical effects.Concentration: 10 mg/mL.
  • Rate: Based on patient's weight (see Route/Dosage section).
  • Solution Compatibility: D5W, LR, D5/LR, D5/0.45% NaCl, D5/0.2% NaCl
  • Y-Site Compatibility: acyclovir, alfentanil, aminophylline, ampicillin, aztreonam, bumetanide, buprenorphine, butorphanol, calcium gluconate, carboplatin, cefazolin, cefepime, cefotaxime, cefoxitin, ceftriaxone, cefuroxime, chlorpromazine, cisplatin, clindamycin, cyclophosphamide, cyclosporine, cytarabine, dexamethasone, dexmedetomidine, diphenhydramine, dobutamine, dopamine, doxycycline, droperidol, enalaprilat, epinephrine, esmolol, famotidine, fenoldopam, fentanyl, fluconazole, fluorouracil, furosemide, ganciclovir, glycopyrrolate, granisetron, haloperidol, heparin, hydrocortisone sodium succinate, hydromorphone, ifosfamide, imipenem/cilastatin, insulin, isoproterenol, ketamine, labetalol, levorphanol, lidocaine, lorazepam, magnesium sulfate, mannitol, meperidine, milrinone, nafcillin, nalbuphine, naloxone, nitroglycerin, nitroprusside, norepinephrine, paclitaxel, pentobarbital, phenobarbital, potassium chloride, prochlorperazine, propranolol, ranitidine, scopolamine, sodium bicarbonate, succinylcholine, sufentanil, thiopental, ticarcillin/clavulanate, vecuronium
  • Y-Site Incompatibility: amikacin, amphotericin B colloidal, calcium chloride, ciprofloxacin, diazepam, digoxin, doripenem, doxorubicin, gentamicin, levofloxacin, methotrexate, methylpredisolone sodium succinate, metoclopramide, mitoxantrone, phenytoin, tobramycin, verapamil

Patient/Family Teaching

  • Inform patient that this medication will decrease mental recall of the procedure.
  • May cause drowsiness or dizziness. Advise patient to request assistance prior to ambulation and transfer and to avoid driving or other activities requiring alertness for 24 hr following administration.
  • Advise patient to avoid alcohol or other CNS depressants without the advice of a health care professional for 24 hr following administration.

Evaluation/Desired Outcomes

  • Induction and maintenance of anesthesia.
    • Amnesia.
  • Sedation in mechanically ventilated patients in an intensive care setting.
Drug Guide, © 2015 Farlex and Partners


A brand name for PROPOFOL.
Collins Dictionary of Medicine © Robert M. Youngson 2004, 2005
References in periodicals archive ?
Propofol, marketed as Diprivan among other names, is a short-acting medication that results in a decreased level of consciousness.
The protocol is as follows: A TCI of propofol (Diprivan 1% pre-filled syringe 10 mg/ml, AstraZeneca UK Limited.) was administered using the Diprifusor [sup]™ (software version 2.0, Graseby 3500 Syringe Pump, Smiths Medical, Watford, UK), which uses the Marsh pharmacokinetic model.
A comparison of Diprivan and thiopental for the induction of anesthesia.
Anesthesia was maintained with propofol 0.05 mg/kg/min (Diprivan, AstraZeneca Turkiye Ilac Sanayi ve Ticaret Ltd.
However, manual de-torsion of the testes under intravenous anesthesia (diprivan) or spermatic cord block has been reported.
Progesterone, GABA, MAO, and COMT Progesterone via one of its primary metabolites, allopregnanolone, upregulates GABA A receptors, as do benzodiazepines, barbiturates, and propofol (Diprivan) (1-3) Progesterone concentrations in the brain have been shown to 20 times higher than in blood.(4) Progesterone balances the excitatory effects of estrogen and is calming.
M2 EQUITYBITES-August 13, 2014-Fresenius Kabi launches Diprivan (propofol) injectable emulsion in 10mL vials
The company manufactures products like EMLA, Diprivan, Betaloc, Atacanf, Tenorectic, Xyloproct, Naropin and Lexxel.
Jackson's Death: Propofol (Diprivan) FAQ, MEDICINE.NET,
Propofol, made by AstraZeneca and marketed as Diprivan, gained notoriety following Jackson's death in 2009.
The injectable agents include droperidol (Inapsinc), etomidare (Amidate), fospropofol (Lusedra), ketamine (Ketalar), methohexital (Brevital), midazolam (Versed), propofol (Diprivan), and sodium thiopental (Pentothal).